Why the study?
Does contrast-enhanced CMR accurately identify myocardial fibrosis and correlate with markers of sudden cardiac death risk in patients with hypertrophic cardiomyopathy?
Does contrast-enhanced CMR accurately identify myocardial fibrosis and correlate with markers of sudden cardiac death risk in patients with hypertrophic cardiomyopathy?
In vivo imaging of myocardial fibrosis using LGE CMR correlates with histopathology and classical markers of sudden cardiac death in patients with hypertrophic cardiomyopathy.
May inform fibrosis assessment in end-stage HCM; leaves open incremental SCD risk stratification value.
end-stage disease who underwent heart transplantation. 35 In the implantable cardioverter defibrillator era, increased attention has been given to proper stratification of risk for SCD by identifying more accurate clinical markers since conventional risk factors for SCD have a very low positive predictive value. 1 Therefore, in vivo imaging of myocardial fibrosis by contrast-enhanced cardiovascular magnetic resonance (CMR) and its relation to the risk of SCD, aroused considerable interest. The concordance between in vivo late gadolinium enhancement (LGE) CMR and histopathologic areas of fibrosis has been described mostly in patients with endstage HCM who underwent transplantation. 3 In these patients, LGE correlated with LV hypertrophy, adverse LV remodelling, decrease in LV ejection fraction (EF), and presence of other classical markers of SCD, such as non-sustained ventricular
No takes yet. Share an insight, caveat, or question.
Popescu et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: